In April 2002, the FDA ordered Merck to revise its Vioxx label to contain the new warning. The FDA also said the new study didn't warrant removing the gastrointestinal complications warning that ...

Triggered by concerns over an increased risk of cardiovascular side effects, Merck announced on 30 September the withdrawal of rofecoxib (Vioxx), its leading drug for the management of rheumatoid ...